5th mRNA Process Development & CMC Summit

Key questions include:

• Are current circRNA purification strategies fundamentally overcomplicated – and where can we simplify without compromising quality?
• How do you balance purity, yield, and scalability when designing purification processes for clinical and commercial manufacturing?
• What will define a “fit-for-purpose” purification platform for circRNA as the field moves toward first-in-human and beyond?

• What are the most persistent challenges you face in reducing dsRNA impurities, and where are current purification approaches falling short?
• How are you balancing regulatory expectations for low impurity levels with the technical limitations of existing purification technologies?
• Which purification strategies, platforms, or resins have shown the most promise, and where do gaps still remain?